Journal article
Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation
A El-Jawahri, YB Chen, R Brazauskas, N He, SJ Lee, JM Knight, N Majhail, D Buchbinder, RM Schears, BM Wirk, WA Wood, I Ahmed, M Aljurf, J Szer, SM Beattie, M Battiwalla, C Dandoy, MA Diaz, A D'Souza, CO Freytes Show all
Cancer | WILEY | Published : 2017
DOI: 10.1002/cncr.30546
Abstract
BACKGROUND: To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes post-transplantation. METHODS: We analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n = 3786) or allogeneic (n = 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre-HCT depression requiring treatment versus those without pre-HCT depression. Using Cox regression models, we compared overall survival (OS) between patients with or without depression. We compared the number of days alive and out of the hospital in the first 100 days post-HCT u..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from Alexion; Amgen, Inc.*; Anonymous donation to the Medical College of Wisconsin; Be the Match Foundation; Bristol Myers Squibb Oncology*; Celgene Corporation*; Chimerix, Inc.*; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.*; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jazz Pharmaceuticals, Inc.*; Jeff Gordon Children's Foundation; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Mesoblast; Millennium: The Takeda Oncology Co.*; Miltenyi Biotec, Inc.*; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. (Japan); Oxford Immunotec; Perkin Elmer, Inc.; Pharmacyclics; Sanofi US*; Seattle Genetics; Sigma-Tau Pharmaceuticals; Spectrum Pharmaceuticals, Inc.*; St. Baldrick's Foundation; Sunesis Pharmaceuticals, Inc.*; Swedish Orphan Biovitrum, Inc.; Telomere Diagnostics, Inc.; TerumoBCT; Therakos, Inc.; University of Minnesota; and Wellpoint, Inc.* The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US government. * Corporate members.